Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / BASIC RESEARCH
High expression of hexokinase 2 promotes lung cancer proliferation and metastasis
1
Department of Respiratory, The Third Hospital of Jilin University, Changchun, Jilin, China
Submission date: 2020-02-04
Final revision date: 2020-05-03
Acceptance date: 2020-05-14
Online publication date: 2020-06-23
Publication date: 2026-02-28
Corresponding author
Shaomin Shi
Department of Respiratory The Third Hospital of Jilin University Changchun, Jilin 130031, China
Department of Respiratory The Third Hospital of Jilin University Changchun, Jilin 130031, China
Arch Med Sci 2026;22(1):456-468
KEYWORDS
TOPICS
ABSTRACT
Introduction:
High metabolic plasticity, as one of the hallmarks of multiple cancers, usually promotes cancer growth and metastasis. Therefore, metabolic enzymes could be selective targets in suppressing the growth and invasion of cancer cells. It is generally believed that hexokinase 2 (HK2) catalysing glucose into glucose-6-phosphate is the first step in glucose metabolism. It is unclear, however, if HK2 is involved in lung cancer (LC) proliferation and metastasis.
Material and methods:
Tumours and adjacent tissue from LC patients were used to study the expression of HK2 by RT-PCR and western blot analysis. Several different LC cell lines were used to explore the oncogene function of HK2 via MTS and BrdU assay in vitro, as well as xenografts model and Lung metastasis model in vivo.
Results:
HK2 was upregulated in primary LC tissue and metastatic foci. The expression of HK2 can be modulated by multiple mutations of oncogenes or tumour suppressors, including Kras, p53, and Keap1. Functionally, suppression of HK2 expression by shRNA transfection in LC cell lines hindered lactate production and therefore suppressed cell migration and invasion. The depletion of HK2 also sensitised the LC cells to cisplatin-induced apoptosis, suggesting that HK2 also mediated the chemoresistance in LC. Finally, our in vivo data indicated that stable knockdown of HK2 inhibited xenografted tumour growth, sensitized the tumour response to cisplatin treatment, and decreased the incidence of lung metastasis in nude mice after tail vein injection.
Conclusions:
We demonstrated that HK2 is required for LC cell growth and metastasis in vitro and in vivo, and for its relationship between multiple mutations in LC. Our results revealed that HK2 promotes LC cell proliferation and metastasis in various mutation backgrounds of LC cells, indicating that HK2 is a high-potential therapy target for LC treatment. Our data provide strong evidence that HK2 plays an important role in promoting LC disease progression, and it may be a promising target for lung cancer therapy.
High metabolic plasticity, as one of the hallmarks of multiple cancers, usually promotes cancer growth and metastasis. Therefore, metabolic enzymes could be selective targets in suppressing the growth and invasion of cancer cells. It is generally believed that hexokinase 2 (HK2) catalysing glucose into glucose-6-phosphate is the first step in glucose metabolism. It is unclear, however, if HK2 is involved in lung cancer (LC) proliferation and metastasis.
Material and methods:
Tumours and adjacent tissue from LC patients were used to study the expression of HK2 by RT-PCR and western blot analysis. Several different LC cell lines were used to explore the oncogene function of HK2 via MTS and BrdU assay in vitro, as well as xenografts model and Lung metastasis model in vivo.
Results:
HK2 was upregulated in primary LC tissue and metastatic foci. The expression of HK2 can be modulated by multiple mutations of oncogenes or tumour suppressors, including Kras, p53, and Keap1. Functionally, suppression of HK2 expression by shRNA transfection in LC cell lines hindered lactate production and therefore suppressed cell migration and invasion. The depletion of HK2 also sensitised the LC cells to cisplatin-induced apoptosis, suggesting that HK2 also mediated the chemoresistance in LC. Finally, our in vivo data indicated that stable knockdown of HK2 inhibited xenografted tumour growth, sensitized the tumour response to cisplatin treatment, and decreased the incidence of lung metastasis in nude mice after tail vein injection.
Conclusions:
We demonstrated that HK2 is required for LC cell growth and metastasis in vitro and in vivo, and for its relationship between multiple mutations in LC. Our results revealed that HK2 promotes LC cell proliferation and metastasis in various mutation backgrounds of LC cells, indicating that HK2 is a high-potential therapy target for LC treatment. Our data provide strong evidence that HK2 plays an important role in promoting LC disease progression, and it may be a promising target for lung cancer therapy.
REFERENCES (38)
1.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2.
Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev 2016; 35: 75-91.
3.
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92.
4.
Faubert B, Li KY, Cai L, et al. Lactate metabolism in human lung tumors. Cell 2017; 171: 358-71 e9.
5.
Zhang Y, Zhang R, Ni H. Eriodictyol exerts potent anticancer activity against A549 human lung cancer cell line by inducing mitochondrial-mediated apoptosis, G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signalling pathway. Arch Med Sci 2020; 16: 446-52.
6.
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008; 13: 472-82.
7.
Buchakjian MR, Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 2010; 11: 715-27.
8.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
9.
Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-28.
10.
Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function J Exp Biol 2003; 206: 2049-57.
11.
Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-12.
12.
Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129-34.
13.
Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-26.
14.
Wang L, Xiong H, Wu F, et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep 2014; 8: 1461-74.
15.
Anderson M, Marayati R, Moffitt R, et al. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 2017; 8: 56081-94.
16.
Li H, Lu S, Chen Y, et al. AKT2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via NF-kappaB, HIF1alpha, MMP2, and MMP9 upregulation. Cell Signal 2019; 58: 99-110.
17.
Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25: 4777-86.
18.
Wang W, Liu Z, Zhao L, et al. Hexokinase 2 enhances the metastatic potential of tongue squamous cell carcinoma via the SOD2-H2O2 pathway. Oncotarget 2017; 8: 3344-54.
19.
Wang H, Wang L, Zhang Y, et al. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int 2016; 16: 9.
20.
Kang YT, Hsu WC, Wu CH, et al. Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells. Oncotarget 2017; 8: 105536-52.
21.
DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun 2018; 9: 446.
22.
BACH1, a novel master regulator of metastasis from breast to bone. Bonekey Rep 2012; 1: 189.
23.
Daemen A, Peterson D, Sahu N, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci USA 2015; 112: E4410-7.
24.
Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685-92.
26.
Ma G, Wang C, Lv B, et al. Proteinase-activated receptor-2 enhances Bcl2-like protein-12 expression in lung cancer cells to suppress p53 expression. Arch Med Sci 2019; 15: 1147-53.
27.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
28.
Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-70.
29.
Zhang C, Liu J, Wu R, et al. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget 2014; 5: 5535-46.
30.
Eriksson M, Ambroise G, Ouchida AT, et al. Effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol Cell Biol 2017; 37:pii: e00328-17.
31.
Napoli M, Flores ER. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer 2017; 116: 149-55.
32.
Frank R, Scheffler M, Merkelbach-Bruse S, et al. Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC). Clin Cancer Res 2018; 24: 3087-96.
33.
Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006; 533: 222-39.
34.
Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
35.
Lignitto L, LeBoeuf SE, Homer H, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell 2019; 178: 316-29e18.
36.
Wiel C, Le Gal K, Ibrahim MX, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell 2019; 178: 330-45e22.
37.
Caino MC, Chae YC, Vaira V, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 2013; 123: 2907-20.
38.
Baumann F, Leukel P, Doerfelt A, et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol 2009; 11: 368-80.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
